Related Experiment Videos
Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis
1Intensive Care Unit, Central Hospital of Dandong City, Dandong, Liaoning 118002; Department of Emergency, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
Chinese Medical Journal
|April 12, 2017
Summary
Targeting the programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) pathway shows promise for treating sepsis. Blocking this pathway can reverse immune suppression and restore immune cell function in sepsis patients.
Area of Science:
- Immunology
- Critical Care Medicine
- Pathophysiology
Background:
- Sepsis is a major cause of mortality in intensive care units globally.
- Immunosuppression is a critical pathophysiological mechanism in sepsis.
- The programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) pathway plays a key role in sepsis-induced immunosuppression.
Purpose of the Study:
- To review existing literature on the PD-1/PD-L1 pathway in sepsis.
- To examine the potential of targeting the PD-1/PD-L1 pathway as a novel therapeutic strategy for sepsis.
Main Methods:
- A systematic literature search was conducted on PubMed up to January 31, 2017.
- Included studies encompassed animal models, clinical research, and reviews on PD-1/PD-L1 and sepsis.
- Evaluated data focused on the association between the PD-1/PD-L1 pathway and sepsis.
Main Results:
- Immunomodulatory therapies can reverse sepsis-induced immune cell deactivation.
- Blocking the PD-1/PD-L1 pathway reduces T-cell exhaustion.
- Targeting PD-1/PD-L1 enhances T-cell proliferation and activation.
Conclusions:
- The anti-PD-1/PD-L1 pathway represents a promising therapeutic target for sepsis.
- This review supports further clinical trials to assess the efficacy and safety of PD-1/PD-L1 blockade in sepsis treatment.